// App-Quantinova.ai

: Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Researchers

Presenter

  • Shaji K Kumar

Principal Investigators

  • Erik J Asmus

  • Francis K. Buadi

  • Wilson I. Gonsalves

  • Eli Muchtar

  • David Dingli

  • Melanie Ann Thompson

  • Ronald Go

  • Rahma M Warsame

  • Taxiarchis Kourelis

  • Yi L. Hwa

  • Amie Fonder

  • Miriam A. Hobbs

  • Martha Q. Lacy

  • Angela Dispenzieri

  • Suzanne R. Hayman

  • Nelson Leung

  • Moritz Binder

  • S. Vincent Rajkumar

  • Morie A Gertz

  • Prashant Kapoor

Medical Centers

  • Division of Hematology, Mayo Clinic Rochester, Rochester, MN

  • Division of Clinical Trials & Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

  • Mayo Clinic, Rochester, MN

  • Division of Hematology, Mayo School of Graduate Medical Education, Rochester, MN

  • Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

  • Mayo Clinic College of Medicine, Rochester, MN

  • Biomedical Statistics and Informatics, Mayo Clinic, Rochester

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

  • Ixazomib

  • Insulin tregopil

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved